A
Adnan Tufail
Researcher at Moorfields Eye Hospital
Publications - 274
Citations - 12126
Adnan Tufail is an academic researcher from Moorfields Eye Hospital. The author has contributed to research in topics: Macular degeneration & Visual acuity. The author has an hindex of 52, co-authored 256 publications receiving 9323 citations. Previous affiliations of Adnan Tufail include UCL Institute of Ophthalmology & National Institute for Health Research.
Papers
More filters
Journal ArticleDOI
Reliability of Retinal Pathology Quantification in Age-Related Macular Degeneration: Implications for Clinical Trials and Machine Learning Applications.
Philipp L. Müller,Philipp L. Müller,Philipp L. Müller,Bart Liefers,Bart Liefers,Tim Treis,Filipa Gomes Rodrigues,Filipa Gomes Rodrigues,Abraham Olvera-Barrios,Abraham Olvera-Barrios,Bobby Paul,Narendra Dhingra,Andrew J. Lotery,Clare Bailey,Paul C.J. Taylor,Clarisa I. Sánchez,Clarisa I. Sánchez,Adnan Tufail,Adnan Tufail +18 more
TL;DR: In this paper, the interreader agreement for grading retinal alterations in age-related macular degeneration (AMD) using a reading center setting was investigated using OCT scans of 112 patients with neovascular AMD.
Journal ArticleDOI
Visual benefit versus visual gain: what is the effect of baseline covariants in the treatment arm relative to the control arm? A pooled analysis of ANCHOR and MARINA.
TL;DR: Higher baseline BCVA is associated with lower BCVA gains but a greater likelihood of achieving good final BCVA >69 letters due to smaller gains needed to achieve response.
Journal ArticleDOI
Modelling Cost Effectiveness in Neovascular Age-Related Macular Degeneration: The Impact of Using Contrast Sensitivity vs. Visual Acuity
TL;DR: There is considerable structural uncertainty associated with the choice of outcome for modelling the cost effectiveness of AMD treatments, and bevacizumab has a higher incremental QALY gain and more favourable incremental cost-effectiveness ratio when cost effectiveness is assessed using contrast sensitivity outcomes compared with using visual acuity outcomes.
A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS
R Belfort,DA Goldstein,DW Johnson,SE Mansour,C Muccioli,JD Sheppard,J Mora-Durate,CK Chan,Alan G. Palestine,J. E. A. Perez,M. J. Cornish,Gary N. Holland,S. S. Ransome,Adnan Tufail,J. M. Weisz,Davis,LD Hubbard,J.R. Armstrong,D Hurlburt,M. Vanderhoof-Young,S. T. Crooke,DL Kisner,J.W. Chandler,K. R. Frost,S. L. Hutcherson,RJ Whitley,L.R. Grillone,R. Lanz +27 more
Journal ArticleDOI
Natural history and effect of therapeutic interventions on subretinal fluid causing foveal detachment in macular telangiectasia type 2
Hemal Mehta,Hemal Mehta,Simone Müller,Catherine A Egan,Simona Degli Esposti,Adnan Tufail,Dawn A Sim,Frank G. Holz,A C Browning,Winfried M Amoaku,Peter Charbel Issa,Mark C Gillies +11 more
TL;DR: Intervention with intravitreal anti-VEGF or steroid therapy may not be necessary as the natural history of this unusual MacTel phenotype is not characterised by rapid visual decline.